Lack of interaction between valaciclovir, the L-valyl ester of acyclovir, and Maalox antacid

Journal of Antimicrobial Chemotherapy

Volumn 37, Issue 2, 1996, Pages 383-387

  De Bony, Florence ^a   Bidault, Roselyne ^a   Peck, Richard ^b   Posner, John ^b  

^a Laboratoire Glaxo Wellcome   (France)

^b WELLCOME RESEARCH LABORATORIES   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ACICLOVIR; ALUMINUM MAGNESIUM HYDROXIDE; ANTACID AGENT; ANTIVIRUS AGENT; ESTER; VALACICLOVIR;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; FEMALE; HERPES SIMPLEX VIRUS; HUMAN; HUMAN EXPERIMENT; MALE; NORMAL HUMAN; ORAL DRUG ADMINISTRATION; STOMACH PH; TIME; VARICELLA ZOSTER VIRUS; VIRUS INFECTION;

ACYCLOVIR; ADULT; ALUMINUM HYDROXIDE; ANALYSIS OF VARIANCE; ANTACIDS; ANTIVIRAL AGENTS; DRUG COMBINATIONS; DRUG INTERACTIONS; FEMALE; HUMANS; MAGNESIUM HYDROXIDE; MALE; PRODRUGS; REFERENCE VALUES; VALINE;

EID: 0029991981     PISSN: 03057453     EISSN: None     Source Type: Journal    
DOI: 10.1093/jac/37.2.383     Document Type: Article

References (9)

1. Balfour, H. H., Clace, B. A., Stapleton, J. T., Simmons, R. L. & Fryd, D. S. (1989). A randomised placebo-controlled trial of oral aciclovir for the prevention of cytomegalovirus disease in recipients of renal allografts. New England Journal of Medicine 320, 1381-7.
2. Burnette, T. C. & de Miranda, P. (1993). Purification and characterization of an enzyme from rat liver that hydrolyzes 256U87. the L-valyl ester prodrug of aciclovir (Zovirax). Antiviral Research 20, Suppl. 1, 115.
3. Gugler, R. & Allgayer, H. (1990). Effects of antacids on the clinical pharmacokinetics of drugs. An update. Clinical Pharmacokinetics 18, 210-9.
4. Meyers, J. D., Reed, E. C., Shepp, D. H , Thornquist, M., Dandliker, P. S., Vicary, C. A. et al. (1988). Aciclovir for prevention of cytomegalovirus infection and disease after allogeneic marrow transplantation. New England Journal of Medicine 318, 70-5.
5. Prentice, H. G., Gluckman, E., Powles, R. L., Ljungman, P., Milpied, N. J., Ranada, J. M. F. et al. (1994). Impact of long-term aciclovir on cytomegalovirus infection and survival after allogenic bone marrow transplantation. Lancet 343, 749-53.
6. Quinn, R. P., de Miranda, P., Gerald, L. & Good, S. S. (1979). A sensitive radioimmunoassay for the antiviral agent BW248U [9-(2-hydroxyethoxymethyl)guanine]. Analytical Biochemistry 98, 319-28.
7. Rolan, P. E., Maillot, F., On, N. T. & Posner, J. (1993). The effects of cimetidine and probenecid on the conversion of a valine ester of aciclovir, 256U, to aciclovir and aciclovir renal clearance in healthy volunteers. British Journal of Clinical Pharmacology 35, 533 P.
8. Wagstaff, A. J., Faulds, D. & Goa, K. L. (1994). Aciclovir - a reappraisal of its antiviral activity, pharmacokinetic properties and therapeutic efficacy. Drugs 47, 153-205.
9. Weller, S., Blum, M. R., Doucette, M., Burnette, T., Cederberg, D. M., de Miranda, P. et al. (1993). Pharmacokinetics of the aciclovir pro-drug valaciclovir after escalating single and multiple-dose administration to normal volunteers. Clinical Pharmacology and Therapeutics 54, 595-605.